CN115109118A - Method for solid-phase synthesis of DS-8201 intermediate and preparation method of DS-8201 - Google Patents

Method for solid-phase synthesis of DS-8201 intermediate and preparation method of DS-8201 Download PDF

Info

Publication number
CN115109118A
CN115109118A CN202110295018.9A CN202110295018A CN115109118A CN 115109118 A CN115109118 A CN 115109118A CN 202110295018 A CN202110295018 A CN 202110295018A CN 115109118 A CN115109118 A CN 115109118A
Authority
CN
China
Prior art keywords
compound
fmoc
solid
coupling
dcm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110295018.9A
Other languages
Chinese (zh)
Inventor
宋云松
甄文腾
池建文
顾家宁
黄仰青
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brightgene Bio Medical Technology Co Ltd
Original Assignee
Brightgene Bio Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brightgene Bio Medical Technology Co Ltd filed Critical Brightgene Bio Medical Technology Co Ltd
Priority to CN202110295018.9A priority Critical patent/CN115109118A/en
Publication of CN115109118A publication Critical patent/CN115109118A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to the technical field of drug synthesis, in particular to a method for solid-phase synthesis of a DS-8201 intermediate and a preparation method of DS-8201. The method for solid-phase synthesis of the DS-8201 intermediate comprises the steps of coupling the hydroxyl end of a compound 5 to solid-phase resin, sequentially splicing Fmoc-Phe-OH, glycine analogue, 6-maleimidocaproic acid or succinimido ester thereof, quickly and efficiently synthesizing a linker fragment by using a solid-phase synthesis method, wherein solid-phase synthesis does not need purification in each step, only the residual reagents/raw materials need to be washed after condensation in each step, and finally the linker is cut off from branches to obtain the linker with higher purity.

Description

Method for solid-phase synthesis of DS-8201 intermediate and preparation method of DS-8201
Technical Field
The invention relates to the technical field of drug synthesis, in particular to a method for solid-phase synthesis of a DS-8201 intermediate and a preparation method of DS-8201.
Background
DS-8201 is an antibody conjugate drug (ADC) targeting Her2, which is prepared by coupling humanized anti-Her 2 antibody trastuzumab (herceptin) with a topoisomerase-I inhibitor camptothecin derivative (DX-8951 derivative DXd) and conjugating the antibody with a tetrapeptide (GGFG) linker. The linker-payload structure of DS-8201 is shown as follows:
Figure BDA0002984013350000011
the first three commonly owned patent WO2014057687A1 discloses three synthetic routes for DS-8201, as follows:
Figure BDA0002984013350000012
Figure BDA0002984013350000021
the synthesis methods all use a liquid phase synthesis method, and the route 1 introduces the Yicetikang too early, the Yicetikang participates in 5-step reaction, repeated deprotection is needed, and the yield is low; the route 2 is optimized, but the Yixingtang still participates in multi-step reaction, so that the cost is still high; the route 3 is improved, the linker is synthesized and then condensed with the ixitancan, although the steps of the reaction of the ixitancan are reduced, and the cost of the ixitancan is reduced, the synthesis of the linker fragment is still complicated, the deprotection is carried out in a repeated liquid phase, each step needs to be purified, the yield is low, the cost is high, the efficiency is low, and the method is not suitable for industrial production.
Therefore, the development of a synthesis method of the linker and DS-8201, which is simple, convenient, low in cost and suitable for industrial production, has a very good application prospect.
Disclosure of Invention
The first purpose of the invention is to provide a method for solid-phase synthesis of a DS-8201 intermediate, which has simple steps and is suitable for industrial production.
The second purpose of the invention is to provide a preparation method of DS-8201.
In order to achieve the purpose, the technical scheme of the invention is as follows:
a method for solid phase synthesis of a DS-8201 intermediate, comprising the following solid phase peptide synthesis route:
Figure BDA0002984013350000031
wherein the glycine analogue is Fmoc-Gly-OH or Fmoc-Gly-Gly-OH, and the Fmoc is fluorenylmethyloxycarbonyl.
When the glycine analogue is Fmoc-Gly-OH, Fmoc-Gly-OH and Fmoc-Gly-OH are required to be coupled to the solid-phase resin in sequence.
The preparation method of the DS-8201 intermediate by solid phase synthesis adopts an Fmoc solid phase synthesis method, sequentially couples the compound 5, Fmoc-Phe-OH, glycine analogue, 6-maleimide caproic acid or succinimide ester thereof to solid phase resin, then washes and dries, and adds a cracking reagent for cracking reaction to obtain the compound 6.
The solid phase Resin is 2-CTC Resin or Merrifield Resin; the degree of substitution of the solid phase resin is 0.2 to 2.0 mmol/g.
The coupling reagent adopted by the coupling is a carbodiimide type condensing agent, a phosphorus positive ion type condensing agent or a urea positive ion type condensing agent.
The cracking reagent is 0.5-5% TFA/DCM, 30% AcOH/DCM or AcOH/TFE/DCM, and the cracking time is 1-5 h. The percentage is volume percentage.
Specifically, the coupling reagent used for the above coupling is any one or more of HOBt, HOAt, HOOBt, HOPyU, TBTU, HBPyU, HBPipU, HBMDU, HATU, HAPyU, HAMDU, TAPipU, HDTU, HPyOPfp, HPySPfp, HAPyTU, TOTU, HAPipU, BOP-Cl, FDP, FDPP, DEPBT, EEDQ, EDC.HCl, DCC, DIC, DIEA, and TEA.
Preferably, the coupling reagent is used by mixing HOBt, HOAt or HOOBt with any one of EDC.HCl, DCC and DIC.
Preferably, when the above coupling reagent is used, DIEA or TEA is used in combination with any one of HBMDU, HATU, HAPyU, HAMDU, TAPipU, HDTU, HPyOPfp, HPySPfp, HAPyTU, TOTU, HAPipU, BOP-Cl, FDP, FDPP, DEPBT and EEDQ.
In the cracking reagent AcOH/TFE/DCM, the volume ratio of AcOH to TFE to DCM is 0.5-2: 1-4: 4 to 8.5.
Preferably, the volume ratio of the AcOH, the TFE and the DCM is 1: 2: 7.
compound 5 was coupled to the solid phase resin as described above, followed by Fmoc-deprotection using piperidine/DMF, followed by Fmoc-Phe-OH coupling.
After the cracking reaction, concentrating, adding MTBE for precipitation, washing, purifying and concentrating to obtain a compound 6.
When the cracking agent is 0.5-5% TFA/DCM, an organic base is added to neutralize the acid after the cracking reaction, preferably, the organic base is pyridine, triethylamine or DIEA.
The washing agent adopted by the washing is any one or more of DMF, DCM, methanol, ethyl acetate, methyl tert-butyl ether and acetone.
Preferably, in the above method, the molar ratio of the solid phase resin to the amino acid used may be 1.0: 1.0 to 5.0. It is understood that the molar ratio is not limited to this range, and it is theoretically possible to use the amino acid in an amount not exceeding the maximum loading of the solid phase resin.
Preferably, in the above process, the molar ratio of amino acid used to coupling reagent may be 1.0: 1.0 to 5.5. It is understood that the molar ratio is not limited to this range, and the amount of the coupling agent capable of supporting the amino acid on the resin is theoretically possible.
A preparation method of DS-8201 comprises the following steps:
Figure BDA0002984013350000041
1) compound 6 was prepared using the above method;
2) and mixing the compound 6, the compound 7 and an organic solvent, cooling to below 10 ℃, adding TBTU and DIEA, heating to room temperature, and reacting for 0.5-3 hours to obtain a DS-8201 crude product, namely a compound 8.
The organic solvent in the step 2) is DMF.
The invention relates to a method for solid-phase synthesis of a DS-8201 intermediate, which comprises the steps of coupling a hydroxyl end of a compound 5 to solid-phase resin, sequentially splicing Fmoc-Phe-OH, a glycine analogue and 6-maleimide caproic acid or succinimide ester thereof, and quickly and efficiently synthesizing a linker fragment by using a solid-phase synthesis method.
According to the preparation method of the DS-8201, the linker is prepared by adopting solid-phase peptide synthesis, then the linker and the Icetic are condensed and spliced by adopting a TBTU and DIEA condensing agent, and the DS-8201 can be obtained by reacting at room temperature for 1-3 h, so that the production cost is reduced, and the production efficiency is improved.
Drawings
FIG. 1 is a LC-MS spectrum of Compound 6;
FIG. 2 is a nuclear magnetic spectrum of Compound 6;
FIG. 3 is an LC-MS spectrum of Compound 8;
FIG. 4 is a nuclear magnetic spectrum of Compound 8;
figure 5 is an HPLC purity profile of compound 8.
Detailed Description
Example 1
Synthesis of Compound 5:
Figure BDA0002984013350000051
synthesis of Compound 2
10.00g of Compound 1(1.0eq), 300mL of tetrahydrofuran, 100mL of toluene, 2.68g of pyridine (1.2eq) and 15.01g of lead tetraacetate (1.2eq) were charged into a 500mL three-necked flask, and heated under reflux, and after the TLC monitoring reaction was completed, the temperature was lowered to room temperature, and insoluble matter was removed by filtration, and after concentration, ethyl acetate was added, and after washing with dilute hydrochloric acid and washing with sodium bicarbonate, the mixture was concentrated, and after column chromatography, an off-white solid compound was obtained in an amount of 27.30 g with a yield of 70.2%.
LC/MS(m/z):calcd for C 20 H 20 N 2 O 5 368.14；found 369[M+H] + ,367[M-H] - .
Synthesis of Compound 4
7.00g of Compound 2(1.0eq), 9.47g of Compound 3(3.0eq), 100mL of tetrahydrofuran, and 4.26g of Potassium tert-butoxide (2.0eq) were charged into a 250mL three-necked flask, and after stirring at room temperature for 0.5 hour, water and dichloromethane were added to the reaction mixture to extract and fractionate the mixture, and the organic phase was collected, after concentration, 100mL of water and 3.19g of sodium bicarbonate (2.0eq) were added, and after concentration, 7.05g of Fmoc-OSU (fluorenylmethoxycarbonylsuccinimid, 1.1eq) in 100mL of ethyleneglycol dimethyl ether was added, and then 50mL of tetrahydrofuran was added, and after stirring at room temperature, after TLC monitoring reaction, ethyl acetate was added after concentration to extract, diluted hydrochloric acid was washed, sodium bicarbonate was washed and then concentrated to obtain a white-like solid compound 45.12 g, with a yield of 56.8%.
LC/MS(m/z):calcd for C 27 H 26 N 2 O 6 474.18；found 475[M+H] + .
Synthesis of Compound 5
4.00g of Compound 4(1.0eq), 50mL of methanol and 0.4g of palladium on carbon were added to a 250mL hydrogenation vessel, and after displacement with nitrogen, hydrogen was introduced while maintaining 4 atmospheres, and the reaction was carried out at room temperature for 2 hours, and after completion of the TLC monitoring reaction, the mixture was filtered and concentrated to obtain 53.01 g of off-white solid compound with a yield of 92.8%.
LC/MS(m/z):calcd for C 20 H 20 N 2 O 6 384.13；found 385[M+H] + ,383[M-H] - .
Example 2
Synthesis of Compound 6
Figure BDA0002984013350000061
Weighing 16.25 g (6.5mmol) of 2-CTC Resin with a degree of substitution of 0.40mmol/g into a 500ml solid phase reaction column, adding 200ml DCM (dichloromethane), 2.50g (6.5mmol) of compound 5, 2.52g (19.5mmol) of DIEA (N, N-diisopropylethylamine), and carrying out nitrogen bubbling reaction for 2 h; then 16ml methanol was added, 2.52g DIEA was reacted for 1h, the resin was washed three times with DMF, the Fmoc protecting group was removed with 20% piperidine/DMF for 20min and washed 6 times with DMF, after which 5.04g (13.0mmol) Fmoc-Phe-OH, 1.93g (14.3mmol) HOBt, 1.80g (14.3mmol) DIC (N, N-diisopropylcarbodiimide) were weighed, dissolved with DMF, added to the reaction column, reacted for 2h, the resin was washed three times with DMF, the Fmoc protecting group was removed with 20% piperidine/DMF for 20min, washed 6 times with DMF and washed 3 times with DCM. The coupling operation is repeated, and Fmoc-Gly-OH, Fmoc-Gly-OH and 6-maleimide caproic acid are sequentially coupled according to peptide sequences. After the reaction is finished, the resin is shrunk by methanol, and 20.25g of peptide resin is obtained after vacuum drying;
the resulting 20.25g peptide resin was added to a 500ml single neck flask, 250ml DCM solution prepared with 1% TFA was added to the flask, reacted at room temperature for 2.0 hours, the resin was filtered off, pyridine was added to neutralize TFA, the solvent was removed by concentration, 200ml methyl t-butyl ether was added to precipitate, slurried, filtered, and the filter cake was collected to give compound 6 as white in 2.56g yield 64%.
LC/MS(m/z):calcd for C 28 H 36 N 6 O 10 616.25；found 615.25[M-H] - The LC-MS diagram of compound 6 is shown in figure 1 and the nmr diagram of compound 6 is shown in figure 2.
In other embodiments, the coupling reagent may be HOAt or HOOBt used in combination with any one of EDC.HCl, DCC, and DIC.
In other embodiments, the coupling reagent may also be DIEA or TEA used in combination with any one of HBMDU, HATU, HAPyU, HAMDU, TAPipU, HDTU, HPyOPfp, HPySPfp, HAPyTU, TOTU, HAPipU, BOP-Cl, FDP, FDPP, DEPBT, EEDQ.
In other embodiments, the cracking reagent may also be 30% AcOH/DCM or AcOH/TFE/DCM, wherein the volume ratio of AcOH, TFE, DCM is 1: 2: 7.
example 3
Synthesis of Compound 6
This example differs from example 2 only in that 6-maleimidocaproic acid in example 2 was replaced with 6- (maleimido) caproic acid succinimidyl ester.
Example 4
Synthesis of Compound 6
This example differs from example 2 only in that "Fmoc-Gly-OH, 6-maleimidocaproic acid coupled in sequence according to the peptide sequence" in example 2 was replaced by "Fmoc-Gly-Gly-OH, 6-maleimidocaproic acid coupled in sequence according to the peptide sequence".
Example 5
Synthesis of Compound 8
Figure BDA0002984013350000071
Adding 1.22g of compound 6(1.05eq) and 1.00g of compound 7(1.00eq) into a 25mL three-necked flask and 10mL of DMF, cooling to below 10 ℃, adding 0.63g of TBTU (1.05eq) and 0.73g of DIEA (3.0eq), heating to room temperature for reacting for 1h, after TLC monitoring reaction is finished, pouring the reaction liquid into water, extracting for 2 times by ethyl acetate, combining organic phases, washing by dilute hydrochloric acid and sodium bicarbonate solution, washing by saturated saline, drying by anhydrous sodium sulfate, concentrating to obtain a crude product, and performing column chromatography on the crude product (DCM: MeOH: 200: 1-10: 1) to obtain 81.59 g of a light yellow solid compound with the yield of 81.5%. The LC-MS pattern of compound 8 is shown in FIG. 3, the nuclear magnetic pattern is shown in FIG. 4, and the HPLC purity pattern is shown in FIG. 5.
LC/MS(m/z):calcd for C 52 H 56 FN 9 O 13 1033.40；found 1032.25[M-H] - .
Various other modifications and changes may be made by those skilled in the art based on the above-described technical solutions and concepts, and all such modifications and changes should fall within the scope of the claims of the present invention.

Claims (10)

1. A method for solid phase synthesis of a DS-8201 intermediate comprising the following solid phase peptide synthesis route:
Figure FDA0002984013340000011
wherein the glycine analogue is Fmoc-Gly-OH or Fmoc-Gly-Gly-OH, and Fmoc is fluorenylmethyloxycarbonyl.
2. The method of claim 1, wherein the compound 5, Fmoc-Phe-OH, glycine analog, 6-maleimidocaproic acid or succinimidyl ester thereof are sequentially coupled to a solid resin by Fmoc solid phase synthesis, and then washed and dried, and a cleavage reagent is added for cleavage reaction to obtain the compound 6.
3. The method of claim 2, wherein the solid phase Resin is 2-CTC Resin or Merrifield Resin; the degree of substitution of the solid phase resin is 0.2 to 2.0 mmol/g.
4. The method according to claim 2, wherein the coupling reagent used for the coupling is a carbodiimide type condensing agent, a phosphorus cationic type condensing agent or a urea cationic type condensing agent.
5. The method of claim 2, wherein the cleavage reagent is 0.5-5% TFA/DCM, 30% AcOH/DCM or AcOH/TFE/DCM, and the cleavage time is 1-5 h.
6. The method according to claim 2, wherein the coupling reagent used for the coupling is any one or more of HOBt, HOAt, HOOBt, HOPyU, TBTU, HBPyU, HBPipU, HBMDU, HATU, HAPyU, HAMDU, TAPipU, HDTU, HPyOPfp, HPySPfp, HAPyTU, TOTU, HAPipU, BOP-Cl, FDP, FDPP, DEPBT, EEDQ, EDC.HCl, DCC, DIC, DIEA, TEA.
7. The method of claim 5, wherein in the cracking reagent AcOH/TFE/DCM, the volume ratio of AcOH, TFE and DCM is 0.5-2: 1-4: 4 to 8.5.
8. The method of claim 2, wherein the Fmoc-protecting group is removed with piperidine/DMF after coupling compound 5 to the solid phase resin, followed by coupling Fmoc-Phe-OH.
9. The process of claim 2, wherein the cleavage reaction is followed by concentration, precipitation with MTBE, washing, purification and concentration to obtain compound 6.
10. A preparation method of DS-8201 is characterized by comprising the following steps:
Figure FDA0002984013340000021
1) preparing compound 6 using the method of any one of claims 1-9;
2) and mixing the compound 6, the compound 7 and an organic solvent, cooling to below 10 ℃, adding TBTU and DIEA, heating to room temperature, and reacting for 0.5-3 h to obtain a DS-8201 crude product, namely a compound 8.
CN202110295018.9A 2021-03-19 2021-03-19 Method for solid-phase synthesis of DS-8201 intermediate and preparation method of DS-8201 Pending CN115109118A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110295018.9A CN115109118A (en) 2021-03-19 2021-03-19 Method for solid-phase synthesis of DS-8201 intermediate and preparation method of DS-8201

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110295018.9A CN115109118A (en) 2021-03-19 2021-03-19 Method for solid-phase synthesis of DS-8201 intermediate and preparation method of DS-8201

Publications (1)

Publication Number Publication Date
CN115109118A true CN115109118A (en) 2022-09-27

Family

ID=83323965

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110295018.9A Pending CN115109118A (en) 2021-03-19 2021-03-19 Method for solid-phase synthesis of DS-8201 intermediate and preparation method of DS-8201

Country Status (1)

Country Link
CN (1) CN115109118A (en)

Similar Documents

Publication Publication Date Title
CN109134602B (en) Solid phase preparation method of efficient prostate specific membrane antigen ligand PSMA-617
JP7139511B2 (en) Method for producing peptide compound, protecting group-forming reagent, and condensed polycyclic aromatic hydrocarbon compound
CN109575109B (en) Method for preparing degarelix by fragment condensation
CN112386707B (en) Tumor targeting polypeptide drug conjugate and preparation method thereof
KR20100036326A (en) Process for the production of pramlintide
CN108218957B (en) Method for preparing AMG416 by combining solid phase and liquid phase
CN110256277B (en) Compound containing fluorene ring structure and application thereof
WO2023089594A1 (en) Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof
CN112585153B (en) Compound or salt thereof, and preparation method and application thereof
CN115109118A (en) Method for solid-phase synthesis of DS-8201 intermediate and preparation method of DS-8201
CN111454180A (en) Somalutide side chain intermediate and preparation method thereof
CN109988213B (en) Compound for polypeptide liquid phase synthesis carrier and preparation method and application thereof
CN110461843B (en) Improved synthesis of NIR fluorescent probes
CN110386964B (en) Solid-liquid synthesis method of leuprorelin
Busnel et al. Synthesis of Fmoc-protected aza-β3-amino acids via reductive amination of glyoxylic acid
CN109988062B (en) Liquid phase spherical carrier and preparation method and application thereof
KR101171095B1 (en) Process for the Preparation of Leuprolide
WO2021026800A1 (en) Method for synthesizing degarelix acetate
CN115340472B (en) Glutamic acid derivative and synthesis method and application thereof
CN111378009A (en) Preparation method of octreotide
CN115368221B (en) Small molecule carrier, preparation method thereof and application thereof in polypeptide synthesis
CN116573992B (en) Non-classical solid phase synthesis carrier and preparation method and application thereof
CN117683114A (en) Preparation method of thymalfasin
CN117964685A (en) Antibody drug conjugate, intermediate thereof, preparation method and application
CN113234122A (en) Synthetic method of double-arm intermediate LND1037 for antibody coupled drug

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination